Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Recent clinical observations have reported the potential benefit of vagus nerve stimulation (VNS) as an adjunctive therapy for pediatric epilepsy. Preliminary evidence suggests that VNS treatment is effective for seizure reduction and mental development in young participants between 3 and 6 years of age who suffer from intractable epilepsy. However, robust clinical evidence for quantifying the difference of the efficacy and safety of VNS treatment in this specific patient population has yet to be reported.
Methods/design: A two-armed, multicenter, randomized, double-blind, prospective trial will be carried out to evaluate whether VNS is beneficial and safe for pediatric epilepsy. Pediatric participants aged between 3 to 6 years old with intractable epilepsy will be recruited and randomly assigned to experimental and control groups with a 1:1 allocation using a computer-generating randomization schedule. Before enrollment, informed consent will be signed by the parents of the participants and the study researchers. Participants in the experimental group will receive electrical stimulation over 24 weeks under standard stimulation parameters. Participants in the control group will not receive any stimulation during the 12 weeks of the double-blind period. The guardians of the participants are required to keep a detailed diary to record seizure activity. Outcome assessments including seizure frequency, Gesell Mental Developmental Scale scores, use of antiepileptic drugs and dosages, and adverse events will be collected at baseline, 6, 12, 18 and/or 24 weeks after electrical stimulation is initiated. The effects of treatment will be analyzed with time and treatment group comparisons.
Discussion: This trial will evaluate quantitative differences in efficacy and safety with/without VNS treatment for pediatric participants aged between 3 to 6 years with intractable epilepsy and will explore whether the current age range of VNS therapy can be expanded.
Trial Registration: ClinicalTrials.gov, ID: NCT03062514 , Registered on 23 February 2017.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6332620 | PMC |
| http://dx.doi.org/10.1186/s13063-018-3087-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Neonatal Refractory Seizures and Hyperammonemia in a Neonate With ALDH7A1 Deficiency.
Clin Case Rep
September 2025
Children's Medical Center, Pediatrics Center of Excellence Tehran University of Medical Sciences Tehran Iran.
Pyridoxine-dependent epilepsy (PDE) is a rare, autosomal recessive neurometabolic disorder characterized by intractable seizures responsive to pyridoxine. We present the case of an 11-day-old female neonate with a history of refractory multifocal seizures beginning on day three of life, accompanied by hepatomegaly, metabolic acidosis, elevated serum ammonia and lactate, and abnormal liver function tests. Despite multiple antiepileptic and metabolic treatments, seizures persisted, and the infant developed progressive metabolic disturbances.
View Article and Find Full Text PDFAnalysis of six CYP450 genetic variants regarding the response to cannabidiol combined with anticonvulsant medication in mexican patients with drug-resistant epilepsy.
Front Pharmacol
August 2025
Unidad de Investigación Médica en Enfermedades Neurológicas, Hospital de Especialidades, "Dr. Bernardo Sepúlveda", Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Ciudad de México, Mexico.
Background: Cannabidiol (CBD) reduces the frequency of seizures in individuals with specific epileptic syndromes, but its effectiveness for other types of drug-resistant epilepsy (DRE) is unclear. CYP450 enzymes primarily metabolize CBD. The aim of this study was to identify CYP450 genotypes regarding the response of CBD treatment concomitant with anti-seizure drugs in patients with DRE.
View Article and Find Full Text PDFCortico-Cortical Evoked Potentials: Automated Localization and Classification of Early and Late Responses.
J Neurosci Methods
September 2025
Department of Electrical and Computer Engineering, University of Alabama at Birmingham, Birmingham, AL, USA.
Background: Cortico-cortical evoked potentials (CCEPs), elicited via single-pulse electrical stimulation, are used to map brain networks. These responses comprise early (N1) and late (N2) components, which reflect direct and indirect cortical connectivity. Reliable identification of these components remains difficult due to substantial variability in amplitude, phase, and timing.
View Article and Find Full Text PDFSynaptic vesicle protein 2A regulates mossy fiber sprouting in a drug-resistant epilepsy rat model via laminin α5/integrin β1.
Brain Res Bull
September 2025
Emergency Department, the affiliated Hospital of Guizhou Medical University, Guiyang (550004), Guizhou Province, PR China. Electronic address:
Drug-resistant epilepsy (DRE) is frequently characterized by pathological mossy fiber sprouting (MFS), which is a defining indicator of aberrant synaptic remodeling within the hippocampus. Despite extensive investigations of the molecular underpinnings of MFS, they remain only partially elucidated. Synaptic vesicle protein 2A (SV2A) is a key modulator of neurotransmitter exocytosis that has been associated with epileptogenesis.
View Article and Find Full Text PDFCommon network related to hyperkinetic seizures revealed by functional lesion network mapping.
Epilepsia
September 2025
Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Objective: This study aims to determine whether the anatomically heterogeneous lesions that cause hyperkinetic seizures (HKS) are connected to a common functional network.
Methods: We identified patients from the Beijing Tiantan-Fengtai Epilepsy Center with HKs as the primary ictal semiology. These included patients had focal seizure-onset zone, here referred to as a "lesion.